T. August Li is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. With extensive interdisciplinary research experience in molecular and clinical pharmacology, and additional focuses in glycobiology, neuroscience, and immunology, August assists clients in preparation and prosecution of patent applications.
Prior to joining the firm, August trained under Dr. Ronald Schnaar at the Johns Hopkins University, where she discovered anti-inflammatory proteoglycans that engage human Siglecs in the esophagus, airways, and brain. She also has studied the roles of gangliosides in glutamate receptor trafficking to understand the seizures and learning disabilities seen in patients with congenital disorders of ganglioside biosynthesis. Her technical expertise spans molecular biology, cell biology, biochemistry, and glycobiology. August obtained her Doctor of Pharmacy at Purdue University, where she gained profound knowledge of pathophysiology, pharmacotherapy, and drug development.
T. August Li is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. With extensive interdisciplinary research experience in molecular and clinical pharmacology, and additional focuses in glycobiology, neuroscience, and immunology, August assists clients in preparation and prosecution of patent applications.
Prior to joining the firm, August trained under Dr. Ronald Schnaar at the Johns Hopkins University, where she discovered anti-inflammatory proteoglycans that engage human Siglecs in the esophagus, airways, and brain. She also has studied the roles of gangliosides in glutamate receptor trafficking to understand the seizures and learning disabilities seen in patients with congenital disorders of ganglioside biosynthesis. Her technical expertise spans molecular biology, cell biology, biochemistry, and glycobiology. August obtained her Doctor of Pharmacy at Purdue University, where she gained profound knowledge of pathophysiology, pharmacotherapy, and drug development.
- Ph.D., Pharmacology and Molecular Sciences, Johns Hopkins University
- Doctor of Pharmacy, Purdue University
- U.S. Patent and Trademark Office
- Ph.D., Pharmacology and Molecular Sciences, Johns Hopkins University
- Doctor of Pharmacy, Purdue University
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A. Gonzalez-Gil, K. Jean, and R.L. Schnaar, “Human sialoglycan ligands for immune inhibitory Siglecs,” Molecular Aspects of Medicine, 2022
- Co-author with A. Gonzalez-Gil, R.N. Porell, S.M. Fernandes, E. Maenpaa, T. Li, P.C. Wong, K. Aoki, M. Tiemeyer, Z.J. Yu, B.C. Orsburn, N.N. Bumpus, R.T. Matthews, and R.L. Schnaar, “Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer’s disease,” 298(6) J. Biol. Chem. 101960, 2022
- Lead author with R. Schnaar, “Congenital Disorders of Ganglioside Biosynthesis,” 156 Prog Mol Biol Transl Sci. 63-82, 2018
- Co-author with A. Gonzalez-Gil, R.N. Porell, S.M. Fernandes, H.E. Tarbox, H.S. Lee, K. Aoki, M. Tiemeyer, J. Kim, and R.L. Schnaar, “Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8,” 20 J Allergy Clin Immunol. 31107-6, 2020
- Co-author with H. Lee, A. Gonzales-Gil, V. Drake, R.L. Schnaar, and J. Kim, “Induction of the endogenous sialoglycan ligand for eosinophil death receptor Siglec-8 in chronic rhinosinusitis with hyperplastic nasal polyposis,” Glycobiology, 2021
- Co-author with Y. Wang, S. Tang, K.E. Harvey, A.E. Salyer, E.K. Rantz, M.A. Lill, and G.H. Hockerman, “Molecular Determinants of the Differential Modulation of Cav1.2 and Cav1.3 by Nifedipine and FPL 64176,” 94(3) Mol Pharmacol 973-983, 2018
Select Publications
- Co-author with A. Gonzalez-Gil, K. Jean, and R.L. Schnaar, “Human sialoglycan ligands for immune inhibitory Siglecs,” Molecular Aspects of Medicine, 2022
- Co-author with A. Gonzalez-Gil, R.N. Porell, S.M. Fernandes, E. Maenpaa, T. Li, P.C. Wong, K. Aoki, M. Tiemeyer, Z.J. Yu, B.C. Orsburn, N.N. Bumpus, R.T. Matthews, and R.L. Schnaar, “Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer’s disease,” 298(6) J. Biol. Chem. 101960, 2022
- Lead author with R. Schnaar, “Congenital Disorders of Ganglioside Biosynthesis,” 156 Prog Mol Biol Transl Sci. 63-82, 2018
- Co-author with A. Gonzalez-Gil, R.N. Porell, S.M. Fernandes, H.E. Tarbox, H.S. Lee, K. Aoki, M. Tiemeyer, J. Kim, and R.L. Schnaar, “Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8,” 20 J Allergy Clin Immunol. 31107-6, 2020
- Co-author with H. Lee, A. Gonzales-Gil, V. Drake, R.L. Schnaar, and J. Kim, “Induction of the endogenous sialoglycan ligand for eosinophil death receptor Siglec-8 in chronic rhinosinusitis with hyperplastic nasal polyposis,” Glycobiology, 2021
- Co-author with Y. Wang, S. Tang, K.E. Harvey, A.E. Salyer, E.K. Rantz, M.A. Lill, and G.H. Hockerman, “Molecular Determinants of the Differential Modulation of Cav1.2 and Cav1.3 by Nifedipine and FPL 64176,” 94(3) Mol Pharmacol 973-983, 2018
- Privacy Policy
- Terms of Use
- Accessibility